References for this Review were found through a search of Pubmed by use of the terms “Birt-Hogg-Dubé syndrome”, “fibrofolliculoma”, or “FLCN”. Reference lists of relevant articles were reviewed. Only full-text articles were included. No date or language restricitons were used. Selected references on associated topics were also included.
ReviewBirt-Hogg-Dubé syndrome: diagnosis and management
Introduction
In 1977, Birt, Hogg, and Dubé described a pedigree in which several family members had skin lesions, consisting of “fibrofolliculomas with trichodiscomas and acrochordons”.1 Birt-Hogg-Dubé syndrome (BHD) is currently defined as an autosomal dominant condition, caused by germline mutations in the FLCN (folliculin) gene, and characterised by skin fibrofolliculomas (figure 1), multiple lung cysts, spontaneous pneumothorax, and renal cancer (Online Mendelian Inheritance in Man #135150).
In 2001, a BHD-associated gene locus was localised to chromosome 17p11.2 by linkage analysis.2, 3 Subsequently, truncating germline mutations were identified in a novel gene, the FLCN (BHD) gene, coding for a protein of unknown function called folliculin (FLCN).4 At present, about 200 families with BHD with pathogenic FLCN mutations have been reported worldwide.5, 6, 7, 8, 9, 10, 11 Roth and colleagues12 first observed bilateral renal cancer in a 61-year-old patient with BHD, in 1993, and now an increased risk of renal cancer in carriers of FLCN mutations is firmly established.13, 14, 15, 16 Multiple lung cysts and spontaneous pneumothorax are also typical complications of the syndrome.14, 17
BHD is probably under-diagnosed because of the wide variability in its clinical expression. Patients might present with renal cancer18, 19, 20 or pneumothorax,6, 21, 22, 23, 24, 25 both of which most often occur sporadically. An estimated 25% of FLCN-mutation carriers older than 20 years of age do not manifest skin lesions,5, 7 whereas other mutation carriers have inconspicuous fibrofolliculomas.
FLCN is located on chromosome 17p11.2; the gene contains 14 exons and encodes folliculin, an evolutionary conserved protein of 579 aminoacids that has no major homology to any other human protein. The function of folliculin is largely unknown. Somatic second-hit mutations identified in BHD-associated renal tumours26 are consistent with a tumour-suppressor function for FLCN. In line with these findings, loss of FLCN mRNA expression was found in renal tumours from patients with BHD.27 However, FLCN mRNA was reported to be strongly expressed in fibrofolliculomas27 and Van Steensel and colleagues28 did not detect loss of heterozygosity in fibrofolliculomas, suggesting that mechanisms of tumorigenesis might differ in renal and skin tumours.
The Nihon rat model for BHD harbours a germline mutation of the rat Flcn orthologue.29 In this animal model, renal cancer develops with high penetrance and with histological features that resemble human chromophobe renal cancer.30 In heterozygous rats, introduction of wild-type Flcn resulted in suppression of renal carcinogenesis.31 Fibromatous tumours associated with surgical incisions were observed; however, this phenomenon has not been reported in humans.32
Lingaas and co-workers33 investigated an inherited cancer syndrome in German Shepherd dogs that showed multifocal renal cystadenocarcinoma and nodular dermatofibrosis. The researchers identified a missense mutation in the canine orthologue of the FLCN gene as the cause of this condition. Second-hit mutations were found in most of the renal tumours and in about a third of the early cystic renal lesions.34, 35 Loss of heterozygosity was not found in skin tumours, a result that is similar in humans.28
The energy-sensing mammalian target of rapamycin (mTOR) pathway has been implicated in the pathogenesis of several hereditary hamartoma syndromes, including BHD.36, 37 Baba and colleagues38 identified a 130-kDa FLCN-interacting protein, FNIP1, and showed that it interacted with 5′AMP-activated protein kinase (AMPK), a protein involved in the mTOR pathway. An FNIP homologue, FNIP2, was found to interact with FLCN and AMPK.39, 40 Two studies described renal tumours and cysts and activation of mTOR in kidney-targeted BHD conditional knockout mice.41, 42 In this animal model, the mTOR-inhibitor rapamycin diminished kidney pathology and increased survival.
The tuberous-sclerosis-complex genes TSC1 and TSC2 encode proteins that regulate the mTOR pathway, and two studies43, 44 highlighted the overlapping clinical features of BHD and tuberous sclerosis complex (skin hamartomas, pulmonary cysts, pneumothorax, and renal tumours). However, yeast (Schizosaccharomyces pombe) that were missing the homologue of human FLCN had a phenotype opposite to yeast deficient for TSC1 or TSC2.43 Downregulation of FLCN leads to mTOR inhibition; by contrast, downregulation of TSC proteins leads to mTOR activation.44 The precise role of folliculin in the mTOR pathway requires further elucidation, and it seems likely that folliculin has several functions. Clarifying the role or roles of folliculin in the molecular pathogenesis of renal cancer might lead to targeted therapy in selected patients.
A germline FLCN mutation was found by sequence analysis, in 51 of 61 families (84%) with BHD.4, 5 Most of the reported pathogenic FLCN mutations are frameshift or nonsense mutations that lead to protein truncation, and a small percentage are splice-site alterations. A mononucleotide tract of eight cytosines within exon 11 has been identified as a hypermutable hotspot;4, 45 the most frequently observed mutation is a cytosine insertion c.1285dupC.5, 7 Very few missense FLCN mutations were reported (eg, 1523A→G [Lys508Arg]).7 Families without a detectable mutation might harbour a genomic deletion or amplification. Recently, an MLPA (Multiplex Ligation-dependent Probe Amplification) kit for FLCN deletion and amplification analysis has been developed. An FLCN mutation database has been established by Wei and colleagues46 and by the European BHD Consortium.47 So far, no gene other than FLCN has been implicated in BHD. In this Review, we summarise the diagnosis and management of BHD. Most of the recommendations are based on expert opinion and may serve as a basis for collaborative studies that could lead to evidence-based recommendations in the future.
Section snippets
The skin
Skin lesions in patients with BHD usually appear after the age of 20 years, as multiple, dome-shaped, whitish papules in the face. These lesions are mainly on the nose and cheeks (figure 1), can be common on the neck, and are sometimes on the trunk or the ears. Histologically, the skin tumours are benign hair follicle tumours designated as fibrofolliculoma (figure 2).
Birt and colleagues1 described fibrofolliculomas, trichodiscomas, and acrochordons as a triad of skin lesions that characterise
Criteria for diagnosis
DNA-based diagnosis of hereditary tumour syndromes has led to new classifications of these conditions based on the underlying gene defects. BHD was formerly defined by the presence of at least five to 10 fibrofolliculomas, of which at least one papule was diagnosed histologically.13, 45 However, the identification of FLCN defects in families with BHD has led to new insights in the penetrance and clinical variability of this syndrome. For example, FLCN-mutation carriers might not manifest any
Genetic testing
FLCN is currently the only gene known to be associated with BHD. DNA-based diagnosis should ideally consist of sequence analysis and a test for exonic deletions and amplifications. Genetic testing should always involve genetic counselling. Mutation detection is recommended even when the clinical diagnosis of BHD is unambiguous: detection of a pathogenic FLCN mutation not only confirms the diagnosis in the index patient but also allows presymptomatic testing of unaffected at-risk relatives. This
The skin
Treatment for skin fibrofolliculomas should be discussed, since the psychological burden of having numerous facial fibrofolliculomas should not be underestimated. However, current therapeutic options are limited. Case reports indicate that laser ablation using an erbium:YAG or fractional CO2 laser is not curative, but gives temporary improvement.79, 80, 81 Al-Daraji and colleagues82 reported successful shave and cautery treatment. Farrant and Emerson83 advocated curettage and hyfrecation of
Conclusion
BHD syndrome was first characterised on the basis of skin fibrofolliculomas—one of the major features. Multiple fibrofolliculomas, histologically verified, are probably diagnostic for the syndrome, although a distinct syndrome with fibrofolliculomas or trichodiscomas only has not been excluded. For the differential diagnosis, tuberous sclerosis complex is an important consideration, since fibrofolliculomas in BHD and angiofibromas in tuberous sclerosis complex have overlapping features. With
Search strategy and selection criteria
References (92)
- et al.
Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2
Am J Hum Genet
(2001) - et al.
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome
Cancer Cell
(2002) - et al.
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome
Am J Hum Genet
(2005) - et al.
Birt-Hogg-Dubé syndrome: clinical and genetic studies of 20 families
J Invest Dermatol
(2008) - et al.
Bilateral renal cell carcinoma in the Birt-Hogg-Dubé syndrome
J Am Acad Dermatol
(1993) - et al.
Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome
J Urol
(2005) - et al.
Chromophobe renal cell carcinoma in a patient with the Birt-Hogg-Dubé syndrome
J Urol
(2002) - et al.
A 4-bp deletion in the Birt-Hogg-Dubé gene (FLCN) causes dominantly inherited spontaneous pneumothorax
Am J Hum Genet
(2005) - et al.
Diagnosis of Birt-Hogg-Dubé syndrome in a patient with spontaneous pneumothorax
Ann Thorac Surg
(2006) - et al.
A 48-year-old woman with skin lesions, renal masses, and spontaneous pneumothorax
Chest
(2007)
Radiological findings in Birt-Hogg-Dubé syndrome: a rare differential for pulmonary cysts and renal tumors
Clin Imaging
Expression of Birt-Hogg-Dubé gene mRNA in normal and neoplastic human tissues
Mod Pathol
Novel mutations in the BHD gene and absence of loss of heterozygosity in fibrofolliculomas of Birt-Hogg-Dubé patients
J Invest Dermatol
Postoperative fibromatosis-type fibromas in the Bhd gene mutant (Nihon) rat
Exp Toxicol Pathol
Identification and characterization of a novel folliculin-interacting protein FNIP2
Gene
The Birt-Hogg-Dube and tuberous sclerosis complex homologs have opposing roles in amino acid homeostasis in Schizosaccharomyces pombe
J Biol Chem
Birt-Hogg-Dubé syndrome: a review of the literature and the differential diagnosis of firm facial papules
J Am Acad Dermatol
Birt-Hogg-Dubé syndrome: a review and presentation of the first case with oral lesions
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
Cysts, cavities, and honeycombing in multisystem disorders: differential diagnosis and findings on thin-section CT
Clin Radiol
Cystic lung disease in Birt-Hogg-Dubé syndrome
Chest
Parotid oncocytoma in the Birt-Hogg-Dubé syndrome
J Am Acad Dermatol
Birt-Hogg-Dubé syndrome: two patients with neural tissue tumors
J Am Acad Dermatol
Treatment of Birt-Hogg-Dubé syndrome with erbium: YAG laser
J Am Acad Dermatol
Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery
J Urol
Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: a 10-year experience
J Urol
Von Hippel-Lindau disease
Lancet
Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons
Arch Dermatol
Birt-Hogg-Dubé syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2
Oncogene
Nonsense mutations in folliculin presenting as isolated familial spontaneous pneumothorax in adults
Am J Respir Crit Care Med
BHD mutations, clinial and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports
J Med Genet
A BHD germline mutation identified in an Asian family with Birt-Hogg-Dubé syndrome
Acta Derm Venereol
Novel mutations in the folliculin gene associated with spontaneous pneumothorax
Eur Respir J
Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN
Clin Cancer Res
Birt-Hogg-Dubé syndrome. A novel marker of kidney neoplasia
Arch Dermatol
Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome
Cancer Epidemiol Biomarkers Prev
Renal tumors in the Birt-Hogg-Dubé syndrome
Am J Surg Pathol
Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome
Am J Respir Crit Care Med
An unusual case of Birt-Hogg-Dubé syndrome with renal involvement
Urol J
Early onset of renal cancer in a family with Birt-Hogg-Dube syndrome
Clin Genet
Recurrent spontaneous pneumothorax as the presenting sign of the Birt-Hogg-Dubé syndrome
Ann Intern Med
High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors
J Natl Cancer Inst
A germ-line insertion in the Birt-Hogg-Dubé (BHD) gene gives rise to the Nihon rat model of inherited renal cancer
Proc Natl Acad Sci USA
Natural history of the Nihon (Bhd gene mutant) rat, a novel model for human Birt-Hogg-Dubé syndrome
Virchows Arch
Transgenic rescue from embryonic lethality and renal carcinogenesis in the Nihon rat model by introduction of a wild-type Bhd gene
Oncogene
A mutation in the canine BHD gen is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog
Hum Mol Genet
Second hits in the FLCN gene in a hereditary renal cancer syndrome in dogs
Mamm Genome
Cited by (441)
Genetic diffuse cystic lung disease in adults
2024, Revue des Maladies RespiratoiresA review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies
2023, International Journal of Biological MacromoleculesMinigene Assay as an Effective Molecular Diagnostic Strategy in Determining the Pathogenicity of Noncanonical Splice-Site Variants in FLCN
2023, Journal of Molecular DiagnosticsThe incidence, pathogenesis, and management of non-clear cell renal cell carcinoma
2024, Therapeutic Advances in UrologyFamilial pulmonary cysts: A clue to diagnose Birt–Hogg–Dubé syndrome: A case report and literature review
2024, Respirology Case Reports